(Q81943280)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18779404%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

review article

1 reference

title

Myeloproliferative disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18779404%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

author name string

Ross L Levine

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18779404%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

D Gary Gilliland

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18779404%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

publication date

1 September 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18779404%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18779404%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

volume

112

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18779404%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18779404%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

page(s)

2190-2198

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18779404%20AND%20SRC:MED&resulttype=core&format=json

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

13 January 2020

cites work

1 reference

12 December 2020

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

1 reference

12 December 2020

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

12 December 2020

Clonal origin of chronic myelocytic leukemia in man

1 reference

12 December 2020

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

12 December 2020

Letter: Bone-marrow responses in polycythemia vera

1 reference

12 December 2020

Polycythemia vera: stem-cell and probable clonal origin of the disease

1 reference

12 December 2020

Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin

1 reference

12 December 2020

Endogenous Erythroid Colony Formation by Peripheral Blood Mononuclear Cells from Patients with Myelofibrosis and Polycythemia Vera

1 reference

12 December 2020

Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.

1 reference

12 December 2020

Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera

1 reference

12 December 2020

Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction

1 reference

12 December 2020

JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin

1 reference

12 December 2020

Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase

1 reference

12 December 2020

Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement

1 reference

12 December 2020

Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes

1 reference

12 December 2020

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

12 December 2020

Clonal analysis of haemopoietic cells in essential thrombocythaemia

1 reference

12 December 2020

Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

1 reference

12 December 2020

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

1 reference

12 December 2020

Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders or myelodysplastic syndromes

1 reference

12 December 2020

From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera

1 reference

12 December 2020

Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene

1 reference

12 December 2020

The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals

1 reference

12 December 2020

Expression of Bcl-x in erythroid precursors from patients with polycythemia vera

1 reference

12 December 2020

Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera

1 reference

12 December 2020

Jak2 is essential for signaling through a variety of cytokine receptors

1 reference

12 December 2020

Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders

1 reference

12 December 2020

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

1 reference

12 December 2020

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

1 reference

12 December 2020

The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).

1 reference

12 December 2020

Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.

1 reference

12 December 2020

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

1 reference

12 December 2020

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

1 reference

12 December 2020

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

1 reference

12 December 2020

Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera

1 reference

12 December 2020

Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells

1 reference

12 December 2020

Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2

1 reference

12 December 2020

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

12 December 2020

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

1 reference

12 December 2020

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

1 reference

12 December 2020

An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.

1 reference

12 December 2020

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

1 reference

12 December 2020

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

1 reference

12 December 2020

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

12 December 2020

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

1 reference

12 December 2020

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

1 reference

12 December 2020

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

1 reference

12 December 2020

Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells

1 reference

12 December 2020

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

1 reference

12 December 2020

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

1 reference

12 December 2020

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model

1 reference

12 December 2020

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

1 reference

12 December 2020

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

12 December 2020

Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation

1 reference

12 December 2020

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

1 reference

12 December 2020

Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice).

1 reference

12 December 2020

The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction

1 reference

12 December 2020

SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma

1 reference

12 December 2020

Some speculations on the myeloproliferative syndromes.

1 reference

12 December 2020

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

12 December 2020

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

12 December 2020

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

12 December 2020

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

12 December 2020

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

1 reference

12 December 2020

Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog

1 reference

12 December 2020

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

1 reference

12 December 2020

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

1 reference

12 December 2020

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

1 reference

12 December 2020

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

1 reference

12 December 2020

Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity

1 reference

12 December 2020

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

1 reference

12 December 2020

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

12 December 2020

Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.

1 reference

12 December 2020

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

1 reference

12 December 2020

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

1 reference

12 December 2020

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

1 reference

12 December 2020

The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia

1 reference

12 December 2020

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules

1 reference

12 December 2020

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

1 reference

12 December 2020

Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis

1 reference

12 December 2020

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

1 reference

12 December 2020

JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling

1 reference

12 December 2020

The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels

1 reference

12 December 2020

Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease

1 reference

12 December 2020

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

1 reference

12 December 2020

Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease

1 reference

12 December 2020

Efficacy and safety of low-dose aspirin in polycythemia vera

1 reference

12 December 2020

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain

1 reference

12 December 2020

10.1182/BLOOD-2008-03-077966

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18779404%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18779404%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

PubMed publication ID

18779404

1 reference